wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 1 - 50 of 372.
1 2 3 4 5 8 Next »

Medicine/Pharmacology - Life Sciences
20.11.2017
Novartis drug Tasigna (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory milestones, including addition of Treatment-free Remission (TFR) data to EU label for adults with Ph+ CML-CP Demonstrates Novartis' continuing commitment to CML patients - Novartis announced today that the European Commission (EC) approved Tasigna (nilotinib
Medicine/Pharmacology - Administration/Government
15.11.2017
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000 deaths
Careers/Employment
15.11.2017
Enrollment now open at the EPFL Extension School
The EPFL Extension School offers online courses with no prerequisites, enabling participants to obtain a Certificate of Open Studies from EPFL.
Innovation/Technology - Administration/Government
15.11.2017
Medicine/Pharmacology
14.11.2017
Physics/Materials Science - Chemistry
14.11.2017
Alloys from the laser printer
Alloys from the laser printer
In the future, new designer alloys for aerospace applications can be manufactured using the 3-D laser melting process (Additive Manufacturing).
Medicine/Pharmacology - Life Sciences
14.11.2017
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA
Medicine/Pharmacology
14.11.2017
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Presentation of results from the Kisqali (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses focused on q
Medicine/Pharmacology - Life Sciences
13.11.2017
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association Scientific Sessions 2017   The analysis showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after initiating canakinumab
Medicine/Pharmacology - Life Sciences
13.11.2017
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a robust data package, even in difficult to treat patients, and is on track to be the first CGRP to market for treatment of patients with chronic or episodic migraine   Cosentyx has strong differentiation based on its unique biology, which has been proven to
Medicine/Pharmacology - Social Sciences
12.11.2017
New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure
Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common physical activity such as exercise and other daily activities at 90 and 180 days after treatment initiation in a retrospective database study in patients with heart failure with reduced ejection fraction (HFrEF) in Germany Entresto significantly reduced levels of NT-proBNP, a key bl
Medicine/Pharmacology - Administration/Government
11.11.2017
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make m
Medicine/Pharmacology - Life Sciences
10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.
Medicine/Pharmacology
10.11.2017
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept   Significantly fewer brolucizumab patients showed signs o
Medicine/Pharmacology - Life Sciences
08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e
Chemistry - Environment/Sustainable Development
07.11.2017
Wood goes high-tech
Wood goes high-tech
Wood could potentially replace petrol in chemistry and concrete in construction, according to studies conducted under the National Research Programme "Resource Wood".
Chemistry - Environment/Sustainable Development
07.11.2017
Wood goes high-tech
Wood goes high-tech
Wood could potentially replace petrol in chemistry and concrete in construction, according to studies conducted under the National Research Programme "Resource Wood".
Physics/Materials Science
07.11.2017
Muscles out of a spray can
Muscles out of a spray can
An artificial heart would be an absolute lifesaver for people with cardiac failure. However, to recreate the complex organ in the laboratory, one would first need to work out how to grow multi-layered, living tissues.
Medicine/Pharmacology - Life Sciences
07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.
Medicine/Pharmacology
07.11.2017
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Structural joint damage in psoriatic art
Medicine/Pharmacology - Life Sciences
06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica
Medicine/Pharmacology
06.11.2017
Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx have no radiographic progression of the spine at 4 years These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favorable and consistent safety profile Cosentyx, the only IL-17A inhibitor approved for AS, is a fully human, highly targeted biologic for first-line use in this
Life Sciences - Medicine/Pharmacology
03.11.2017
Reading our brain chemistry
Reading our brain chemistry
Researchers at EPFLhave developed a new device and analysis method that let doctors measure the neurochemicals in a patient's brain. The Microsystems Laboratory 4 (LMIS4)'ssystem involves collecting microdroplets of cerebral fluid and analyzing them to obtain chemical data that can help doctors diagnose and treat neurodegenerative diseases.
Environment/Sustainable Development - Life Sciences
03.11.2017
Mapping Functional Diversity of Forests with Remote Sensing
Mapping Functional Diversity of Forests with Remote Sensing
Ecological studies have demonstrated positive relationships between plant diversity and ecosystem functioning. Forests with higher functional diversity are generally more productive and stable over long timescales than less diverse forests. Diverse plant communities show increased resource use efficiency and utilization, enhanced ecosystem productivity and stability and can better cope with changing environmental conditions - an insurance effect of biodiversity.
Life Sciences - Environment/Sustainable Development
02.11.2017
UZH Anthropologists Describe Third Orangutan Species
Two species of Indonesian orangutans had previously been officially described and recognized - the Pongo abelii , living on the island of Sumatra, and the Pongo pygmeaeus , endemic to Borneo. In 1997, researchers at the Australian National University discovered an isolated population of orangutans in Batang Toru, a region within the three Tapanuli districts in North Sumatra.
Careers/Employment
02.11.2017
Confederation and the cantons adopt common strategy on exchanges and mobility
Bern, 02.11.2017 - The exchange and mobility strategy aims to make exchanges and mobility a natural part of education pathways, career trajectories and extracurricular activities.
Life Sciences - Medicine/Pharmacology
02.11.2017
How Caries-Causing Bacteria Can Survive in Dental Plaque
How Caries-Causing Bacteria Can Survive in Dental Plaque
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One. Cariogenic bacteria live in biofilm and attack dental enamel by converting sugar and starch into acids that dissolve out calcium from the enamel.
Medicine/Pharmacology - Life Sciences
02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e
Medicine/Pharmacology - Administration/Government
01.11.2017
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia
Physics/Materials Science - Civil Engineering/Traffic Engineering
01.11.2017
Research collaboration for sustainable
Research collaboration for sustainable
Buildings made of reusable components: that is the aim of a research collaboration between Empa and the University of Luxembourg.
Medicine/Pharmacology - Life Sciences
01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl
Event - Environment/Sustainable Development
31.10.2017
Medicine/Pharmacology - Life Sciences
31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated
History/Archeology - Environment/Sustainable Development
31.10.2017
Three ways to preserve a Neolithic site
Three ways to preserve a Neolithic site
An EPFL study commissioned by the Canton of Bern has come up with three possible ways of protecting the Sutz-Lattrigen archaeological site, which offers a rare insight into the lives of pile dwellers.
Life Sciences - Medicine/Pharmacology
30.10.2017
Important Mechanism of Epigenetic Gene Regulation Identified
DNA contains the blueprint of an entire organism. Based on the information in this blueprint, every cell knows what it must become and what function it must perform. Throughout the entire lifespan of an organism, the genetic information has to be read correctly to ensure that genes are active at the right time and in the right cells.
Medicine/Pharmacology - Business/Economics
30.10.2017
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera , a first-in-class RadioLigand Therapy (RLT) app
Medicine/Pharmacology
30.10.2017
Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting , Structural disease progression is a major c
Psychology
30.10.2017
Willingness to Take Risks - a Personality Trait
Willingness to Take Risks - a Personality Trait
People differ in their willingness to take risks. An individual's propensity for risk taking can also vary across domains. However, there is new evidence showing that there is also a general factor of individual risk preference, which remains stable over time - akin to the general Intelligence Quotient (IQ).
Astronomy - Physics/Materials Science
30.10.2017
Claude Nicollier, forever known as the first Swiss man in space
Claude Nicollier, forever known as the first Swiss man in space
Just 25 years ago, Vaud astronaut Claude Nicollier boarded the Space Shuttle Atlantis for the first of what would be four missions in space.
Medicine/Pharmacology - Life Sciences
28.10.2017
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs.
Medicine/Pharmacology
27.10.2017
Life Sciences
27.10.2017
Advanced artificial limbs mapped in the brain
Advanced artificial limbs mapped in the brain
EPFL scientists from the Center for Neuroprosthetics have used functional MRI to show how the brain re-maps motor and sensory pathways following targeted motor and sensory reinnervation (TMSR), a neuroprosthetic approach where residual limb nerves are rerouted towards intact muscles and skin regions to control a robotic limb.
1 2 3 4 5 8 Next »

 
 
Jobs on